Loading
GlyTR1 is an experimental protein from GlyTR Therapeutics that latches onto sugar molecules crowded on cancer cells and pulls immune T cells in to attack. It has been tested only in the laboratory and in animals.
GlyTR1 is a bispecific Glycan-dependent T cell Recruiter developed by GlyTR Therapeutics from work at the University of California, Irvine. It binds beta1,6GlcNAc-branched N-glycans through a lectin domain and engages T cells through CD3. The NIH RePORTER abstract for STTR award 4R42CA302415-02 describes GlyTR1 and GlyTR2 as killing cells with high but not low expression of tumour-associated carbohydrate antigens in preclinical models; there are no human results.
A Glycan-dependent T cell Recruiter: a lectin domain binds beta1,6GlcNAc-branched N-glycans, which are dense on many cancer cells, and an anti-CD3 domain brings T cells to kill them. Connects to CD3.
1.One arm of GlyTR1 binds CD3 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"GlyTR1" OR ABSTRACT:"GlyTR1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GlyTR1, not a curated reading list.
Shares CD3, T-cell engagers (bispecific) and the tag pipeline.
Shares CD3, T-cell engagers (bispecific) and the tag pipeline.
Shares CD3, T-cell engagers (bispecific) and the tag pipeline.
Shares CD3, T-cell engagers (bispecific) and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/